Commentary Non refereed The porcine reproductive and respiratory syndrome quandary. by Part Ii Vaccines et al.
152 Journal of Swine Health and Production — May and June 2005
Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine,
Iowa State University, Ames, Iowa.
This article is available online at http://www.aasv.org/shap.html.
Mengeling WL. The porcine reproductive and respiratory syndrome quandary. Part II: Vaccines and
vaccination strategy.  J Swine Health Prod. 2005;13(3):152–156.
Commentary Non refereed
The porcine reproductive and respiratory syndrome quandary.
Part II: Vaccines and vaccination strategy
William L. Mengeling, DVM, PhD, Diplomate ACVM
T
he ﬁrst vaccine to aid in the pre-
vention of the porcine reproductive
and respiratory syndrome (PRRS)
was registered for use in Spain in 1994. It
comprised an inactivated European strain
of PRRS virus (PRRSV) that had been
propagated in porcine alveolar macrophages.
Later in the same year, the ﬁrst attenuated-
virus vaccine became commercially available
in the United States.1 It comprised a North
American strain of PRRSV that had been
propagated in an established monkey kidney
cell line. Since 1994, a number of addi-
tional vaccines (comprising either attenuated
or inactivated PRRSV) have been developed
in both the United States and Europe.
Each includes a different strain of the virus
of either the North American or European
genotype (Table 1).
Although PRRS vaccines have been used
extensively over the past decade, there have
been recurring questions in regard to their
efﬁcacy, and, in the case of attenuated-virus
vaccines, their safety. As a consequence, a
great deal of time, effort, and ﬁnancial re-
sources have been directly or indirectly de-
voted to a better understanding of PRRS
immunology and the development of what
has sometimes been optimistically referred
to as the next generation of PRRS vaccines.
Just how this might be accomplished is as
yet unclear, and other than the still contro-
versial issue of genotype speciﬁcity,2,3 there
is no deﬁnitive evidence that the original
vaccines are less effective than any of those
developed more recently. But despite disap-
pointments of the past, research on PRRS
immunology, including vaccine develop-
ment, is continuing, perhaps even being
accelerated, largely because of the major
economic impact of the disease4 and the
recent increase in research funding.5 To
provide some indication of the probability
of soon developing better approaches for
PRRS immunoprophylaxis, the following
discussion brieﬂy addresses some of the
advantages and disadvantages of the types
of vaccine that are most likely to be consid-
ered and a possible strategy to increase the
immune response to vaccines currently
available.
Virulent virus
Although virulent virus does not meet the
deﬁnition of a vaccine, it is included here,
because there seems to be a growing ten-
dency in the United States to use virulent
strains of PRRSV in an attempt to induce
immunity for the reproductive facet of the
syndrome.6 In general, the most common
approach – often referred to as planned or
controlled exposure – is as follows. Females
are exposed, before conception and typi-
cally during the acclimatization phase of
gilt development, to the predominant or
only strain of ﬁeld virus circulating in the
herd at the time. Expectations are that any
clinical reaction to the virus will be minimal,
or at least manageable, and the associated
immune response will be directed to the
strain of PRRSV to which the females are
most likely to be at risk during their subse-
quent gestation(s). With the exception of a
possible untoward clinical reaction during
the immunization process, it is difﬁcult to
imagine a more effective way of inducing
protective immunity. However, the poten-
tially negative consequences of purposely
infecting females (destined to join the
breeding herd) with fully virulent PRRSV
are likely to deter most veterinarians and
producers from considering this approach.
Moreover, planned exposure may not al-
ways result in the theorized level of immu-
nity. Notably in two herds that have come
to my attention, reproductive failure was a
consequence of purposeful exposure of
pregnant females to the same strain of ﬁeld
virus previously used for immunization.
Whether it was less severe than it might have
been if a commercially available attenuated-
virus vaccine had been used for immuniza-
tion prior to exposure to virulent virus during
gestation is impossible to evaluate. Addi-
tional details in regard to these two herds,
as well as a herd that was naturally exposed
to what was believed to be the same strain
of virulent virus in each of two succeeding
gestations, have been presented elsewhere.7
But regardless of the level of immunity
provided by exposure to virulent virus be-
fore conception, a clear downside is the
certainty of maintaining such virus in the
herd in perpetuity.
Attenuated-virus (modiﬁed-
live-virus) vaccine
Of all of the types of conventional vaccines
available today, those prepared from at-
tenuated virus are the most likely to provide
the highest level of clinical protection.
They have the potential to replicate exten-
sively over a long period of time in the vac-
cinated pig (the degree of replication may
depend on the level of attenuation) and
thus repeatedly expose the pig’s immune
system to the entire spectrum of viral anti-
gens. Because neutralizing antibody against
PRRSV (ie, antibody that probably plays
an important role in protective immunity
as well as in clearing the virus from a pig) is
slow to develop, this long interval of repli-
cation may be more important for PRRS
immunity than it is for many other viruses.
However, despite the fact that it is probably
the best vaccine of the group in regard to
protection, it still falls short of expectations
in some instances. At one time the biggest
criticism of attenuated virus was its potential
to revert to some degree of virulence if it
were used under conditions that allowed its
sequential passage in naive pigs. This concernJournal of Swine Health and Production — Volume 13, Number 3 153
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for safety is apparently of less concern today,
in that even fully virulent virus is sometimes
being administered to gilts in an attempt to
induce immunity before conception. And
keep in mind that while there are reasonable
concerns about the efﬁcacy of attenuated-
virus vaccines under some ﬁeld conditions,
controlled studies have conﬁrmed their
appreciable protective value when they are
administered well before exposure to virulent
virus, especially in regard to the respiratory
facet of the disease.8,9
Deletion-mutant-virus
vaccine
Assuming that the immunogenic and repli-
cation properties of the virus are not mark-
edly altered by deletion of some part(s) of
the viral genome, deletion-mutant-virus
vaccine should have the ability to stimulate
a protective immune response similar to
that of attenuated-virus vaccine. And on
the plus side, the deletion(s) could result in
either or both of two properties that would
give deletion-mutant-live-virus vaccine an
advantage over conventional live-virus vac-
cines. First, the deletion mutant might be
unable to regain any degree of virulence by
reverse mutation (although it might still do
so as a consequence of recombination). In
fact it might actually be attenuated by the
deletion(s). Second, with the development
of a companion diagnostic test (directed
toward the antigen or epitope coded for by
the deleted portion of the viral genome), it
might be possible to identify pigs exposed
to virulent virus regardless of vaccination
history. Of course, the latter is what is most
often thought of as the salient feature of
deletion-mutant-virus vaccines. Because
virulent PRRSV can persist in an infected
pig for a long period of time, perhaps even
in a previously vaccinated pig, this attribute
might be particularly important should an
eradication program be started (assuming
that vaccination with live virus would still
be allowed during the program). But also
be aware that there is no reason to believe
that a deletion-mutant-live-virus vaccine
would be any more effective in regard to
immunity than would a non-deleted virus,
and it is conceivable that it would be less
so.
The bad news is that it may not be possible,
or it may be at the very least very difﬁcult,
to develop a suitable deletion-mutant-live-
virus vaccine because of the nature of PRRSV
genome. Namely, the genome is a relatively
short, single strand of RNA, and, in addi-
tion, all of the genes that code for structural
proteins may be essential for replication.10,11
To date (to my knowledge), most deletions
have resulted in lethal mutants (ie, the al-
tered genome will no longer replicate infec-
tious virus). This is in stark contrast to the
relative ease with which deletion mutants
have been created with large double-stranded
DNA viruses like pseudorabies (Aujeszky’s
disease) virus. And perhaps the notable
success with pseudorabies virus in both the
development of deletion-mutant-live-virus
vaccines and the use of such vaccines in
eradication programs has resulted in unre-
alistic expectations for PRRSV.
There is also a double challenge faced in
the practical application of a deletion-mu-
tant-virus vaccine in an eradication program.
First, the deleted portion of the viral ge-
nome must be present in all virulent ﬁeld
strains of PRRSV. Otherwise, of course,
some virulent strains would mimic the vac-
cine in regard to the missing “diagnostic
antigen.” Second, the immune response to
the diagnostic antigen (which could be all
or part of a distinct protein, or simply a
single epitope) must always be detectible
via the companion diagnostic test. For ex-
ample, in the case of pseudorabies, it was
shown – fortunately early in the eradication
program – that one of the proposed differ-
ential diagnostic tests was not sufﬁciently
sensitive.12 The reason was that not all in-
fected pigs produced an adequate level of
antibody to test positive, even though the
antigen was present in all ﬁeld strains. This
observation, although seldom mentioned,
was an important contribution to the suc-
cess of the pseudorabies eradication program
in the United States.
1      On the basis of information made available by representatives of the respective companies, these vaccines are marketed in one or
more (usually at least several) countries of each of the designated continents.
2      Suvaxyn-PRRS was originally called Cyblue®. It was the first inactivated-virus PRRS vaccine made available (April 1994) for
commercial use.
3     Ingelvac PRRS MLV was originally called RespPRRS, and later RespPRRS Repro. It was the first attenuated-virus PRRS vaccine
made available (November 1994) for commercial use. It has the widest distribution of any PRRS vaccine and is currently marketed in
at least 20 countries.
4     Boehringer Ingelheim has co-marketing rights.154 Journal of Swine Health and Production — May and June 2005
Inactivated-virus vaccine
In general, inactivated vaccines are used
when the level of immunity they provide,
which is typically less, often considerably
less, than provided by live-virus vaccines, is
judged to be “good enough.” Notable ex-
amples are swine inﬂuenza virus and por-
cine parvovirus vaccines. Unfortunately,
the efﬁcacy of inactivated PRRS vaccines
has been seriously questioned. Because the
issue of inactivated PRRS vaccine and
efﬁcacy has been debated so many times,
often passionately, in so many forums, I
won’t pursue it further in this context.
Other real or potential disadvantages of
inactivated-PRRSV vaccine are cost and
the need in most cases for more than a
single dose to stimulate a measurable anti-
body response.
The biggest advantage of an inactivated-
PRRSV vaccine is that of almost unques-
tioned safety, both real and perceived.
What I mean by the latter is that if there is
any clinical problem, short of the ridiculous,
after the administration of live-virus vaccine,
it is logical to at least consider the vaccine
as the possible culprit. The associated stress
for the swine producer, the veterinarian,
and the vaccine producer can largely be
circumvented by using inactivated vaccine.
That is, it is likely that an inactivated vac-
cine will be considered innocent until
proven otherwise, whereas it is just as likely
that an attenuated-virus vaccine will be
considered guilty until proven otherwise.
On the other hand, from an ethical per-
spective, it is important to be assured that a
particular vaccine is efﬁcacious or the issue
of safety is a moot point.
Inactivated-virus vaccine can also be prepared
from a deletion-mutant virus (either at-
tenuated or virulent if available) or deleted
in some other manner so that vaccination
does not obscure detection of pigs exposed
to virulent live virus. The principle and
limitations would be the same as those de-
scribed above for deletion-mutant-live-virus
vaccines.
Naked DNA vaccine
Our very limited experience with a naked-
DNA-PRRS vaccine (while I was still on
the staff of the National Animal Disease
Center) conﬁrmed that it could be used to
raise antibody against the virus. However,
there was no evidence (among the few pigs
tested) that it provided any clinical protec-
tion. I believe, although I am not sure, that
the same result was obtained by a large
biologics company. It is a safe vaccine from
the standpoint that it can be constructed so
that it does not replicate infectious virus.
In fact, the DNA vaccine we tested coded
for only a single PRRSV protein, namely,
the envelope protein that is thought to be
the most important PRRSV protein for
raising neutralizing antibody. Proteins (an-
tigens), by virtue of being produced within
the DNA-transfected (infected) cell, are
presented to the immune system in the
same way as are those produced in live-
virus-infected cells, which in turn is a route
of presentation that is reported to effectively
stimulate the cell-mediated arm as well as
the humoral arm of the immune system (in
contrast to inactivated virus vaccines and
subunit vaccines that are thought to prima-
rily stimulate the humoral arm of the im-
mune system). One general concern that
has been expressed relative to DNA vaccines,
especially in regard to people, is the possi-
bility that the DNA present in the vaccine
might incorporate into the cell genome of
the vaccine recipient, with some as yet
undeﬁned, but possibly undesirable, result.
Protein subunit vaccine
What was said above about inactivated-virus
vaccines essentially applies to protein-sub-
unit vaccines. In general, only the means
by which they are prepared differ. That is,
inactivated-virus vaccine is, as the name
implies, whole virus that is disabled, usu-
ally by some chemical treatment, so that it
no longer has the ability to replicate, whereas
subunit-protein vaccine (as deﬁned here) is
produced in part through the miracle of
genetic engineering. As an example, one or
more genes (that code for the corresponding
selected proteins) of the PRRSV genome
might be inserted into the genome of an-
other virus such as a baculovirus. The
baculovirus might then be propagated in
cell culture, whereby both baculovirus and
PRRSV proteins would be produced. The
next step might entail puriﬁcation of the
PRRSV proteins to rid the vaccine of at
least most baculovirus and cell proteins.13
Vectored vaccine
In theory, this type of vaccine has a great
deal of merit. The idea is that the gene or
genes of the most important immunogenic
protein or proteins of one or more patho-
genic viruses (those for which we want to
stimulate immunity) are genetically engi-
neered into the genome of another virus
(the vector). The vector does not have to be
a virus, for example it could be a bacterium,
but I will focus on a virus for this short
discussion. When a person or a lower animal
such as a pig is injected with the genetically
altered vector, the vector replicates and not
only codes for its own proteins but also for
proteins corresponding to the inserted
gene(s). Assuming that genetic engineering
can be accomplished satisfactorily, the con-
cept seems very promising. However, there
are a few hurdles, some of which present a
major problem and most of which involve
the selection of suitable vector.
First, the vector must be large enough to
accommodate the inserted gene(s). Prime
candidates are large double-stranded DNA
viruses such as the following that are listed
in the order of their increasing capacity:
adenoviruses, herpes viruses (eg, pseudora-
bies virus), and poxviruses (eg, vaccinia
virus and swinepox virus).
Second, the vector should probably not be
a natural pathogen of pigs, otherwise pigs
might already have antibody to the vector,
which in turn would have the potential to
interfere with the necessary replication of
the vector. Obviously, preexisting antibody
to a vector would have nothing to do with
preexisting antibody – and by inference
preexisting immunity – to the virus or vi-
ruses for which the vaccine was intended.
This is an important point that I will em-
phasize in yet another way. If we try to vac-
cinate for a particular pathogen using a
conventional vaccine and the vaccine is
ineffective because there is preexisting anti-
body, either passively or actively acquired,
we can assume that the vaccine recipient is
already protected, albeit only temporarily
in the case of passively acquired antibody.
On the other hand, if the vaccine is ineffec-
tive because of preexisting antibody against
a vector, we may be left with a completely
susceptible individual in regard to the
pathogens for which the vaccine was in-
tended. On the potentially positive side of
all this is the possibility that if the vaccinated
pig had antibody, eg, passively acquired
antibody, against the virus or viruses to
which immunity is desired, but no antibody
against the vector, the vector, unscathed,
plus its load of inserted genes, might reach
cells of the immune system; and once in-
side such cells, nascent proteins would, at
least in theory, be unaffected by circulating
antibody.14 The vector would thus serve as
a “Trojan horse.” Unfortunately, the practice
may not fully parallel the theory. The pos-
sible reasons will not be discussed here.
Third, if we identify a potential vector for
which the pig will be unlikely to have pre-
existing antibody, we must be sure that the
same vector will replicate extensively in theJournal of Swine Health and Production — Volume 13, Number 3 155
pig so that there will be adequate production
of the coded proteins, ie, those corresponding
to the vectored genes.
Fourth, the vector should be incapable of
infecting another species that might come
in contact with vaccinated pigs, especially if
infection of another species results in clinical
disease. This issue may be even more restric-
tive if the vector has the potential to infect
people (eg, vaccinia virus), because then the
deﬁnition of a potential problem is likely to
be expanded to include those who might be
immunocompromised by a disease such as
AIDS, or a treatment such as chemotherapy.
Imagine the complexities associated with
trying to determine if there would ever be a
problem under such conditions. So while
the concept of a vectored vaccine for PRRSV
is appealing, the practicalities are somewhat
daunting.
Potential for the combined
use of vaccines
There is a possibility that sequential ad-
ministration of more than one type of
PRRS vaccine will result in a level of pro-
tective immunity appreciably greater than
that following the administration of a
single type of vaccine or a single exposure
to virulent virus. Moreover, the combina-
tion may be more effective regardless of
how many times either virulent virus or a
single type of vaccine is administered alone,
ie, the same strain and virulence level ad-
ministered repeatedly.
Such a combination strategy, referred to
previously as the SWINE method of PRRS
(or pathogen) control, was presented re-
cently, along with supporting data, at the
annual meeting of the American Association
of Swine Veterinarians in Toronto.7 Its pur-
pose is to provide protection against maternal
reproductive failure via actively acquired
immunity, as well as clinical disease in
young pigs via passively acquired immu-
nity. In addition to the amelioration of
clinical disease, it has the potential to
markedly reduce shedding of virulent virus.
Its identifying acronym, namely SWINE, is
derived from the ﬁve discrete phases of the
strategy (referred to here as steps for sim-
plicity): “Sensitization,” “Wait,” “Immuni-
zation,” “Neutralization,” and
“Eradication.”
Step 1 is sensitization of the immune system
with either inactivated virus or attenuated
virus beginning when pigs (replacement
gilts or boars) are only a few weeks of age.
Step 2 is to wait at least several months for
appreciable maturation of the immune sys-
tem, particularly for the relevant protective
antigens. Step 3 is to expose sensitized
(primed) gilts (or boars) to virulent virus if
previous sensitization was with either inac-
tivated virus or attenuated virus, or with
attenuated virus if previous sensitization
was with inactivated virus. Assuming that
the latter (ie, inactivated virus for sensitiza-
tion and attenuated virus for immuniza-
tion) would provide an acceptable level of
protective immunity, this would clearly be
the strategy of choice. It would avoid the
periodic reintroduction of virulent virus
into the herd as well as minimize the po-
tential for shedding of attenuated virus.
And please be aware that mention of virulent
virus in this context is not to be construed as a
recommendation for its use, but merely as a
statement of likely immune responsiveness.
Also notice in regard to the above that sen-
sitization and immunization are deﬁned as
such relative to their roles in the SWINE
method of PRRS (pathogen) control; im-
munization is always with a form of the
virus that presumably has a greater propen-
sity for immune stimulation than what was
used for sensitization; and “(pathogen)” is
added to the SWINE method of PRRS
control because there is the likelihood that
the sensitization-wait-immunization steps
can be used simultaneously for any of several
other pathogens that commonly plague the
swine industry. An important point in con-
sidering the use of inactivated vaccine for
sensitization (a possibility not yet ad-
equately tested under controlled conditions)
is that there must be a clear indication of
sensitization. If after administering an inac-
tivated product several times there is no
obvious, measurable evidence of an immune
response, it is unlikely that the immune
system can be considered adequately sensi-
tized. Step 4, neutralization, would logically
follow success of Steps 1, 2, and 3. And the
deﬁnition of neutralization is in the broad
sense referring to prevention of infection
regardless of the means by which it is ac-
complished by the immune response. Step
5, eradication, would be a realistic goal
once the incidence of infection was markedly
reduced.
Unfortunately, there appear to be at least
two major challenges to any near-term,
industry-wide implementation of the SWINE
method of PRRS (pathogen) control. First
is the question of whether genetic suppliers
can provide the estimated 2,500,000 naive
gilts (both antibody-free and virus-free)
needed to annually repopulate commercial
breeding herds – namely the candidates for
Step 1. And except for the unlikely possi-
bility of stimulating (sensitizing) the im-
mune system in the presence of passively
acquired antibody, Step 1 would therefore
be limited to only some of the gilts needed
each year. Second, assuming that inactivated
vaccine is selected for sensitization, there
may be a need to develop a commercial
product that will adequately and consis-
tently sensitize the immune system. It is as
yet unclear whether currently available in-
activated vaccines could fulﬁll this role.
And although attenuated virus can be used
for sensitization, perhaps even in the pres-
ence of a low level of passive acquired anti-
body, its use would not be a realistic possi-
bility unless pigs (from a PRRSV-free herd)
were moved to yet another isolated site for
vaccination, with the assurance that they
would not again be exposed to PRRSV
until they were shipped months later to
destination breeding herds for immuniza-
tion, ie, Step 3. Moreover, managers of the
destination herds would have to have ac-
quiesced to the idea of using virulent virus
for immunization, a procedure not likely to
be widely accepted.
Summary
It is likely that use of conventional attenu-
ated-virus vaccines will continue to be one
of our best tools for the prevention and
control of PRRS. Whether any new ap-
proaches as to how and when vaccines are
administered can enhance their effective-
ness, within the constraints of today’s com-
mercial swine production, remains to be
determined. However, it is conceivable that
at least the principles of the SWINE
method of PRRS (pathogen) control will
play an important role in future strategies
to reduce the economic impact of PRRS
and other infectious diseases that currently
plague the swine industry.
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